Single-cell sequencing of a novel model of neonatal bile duct ligation in mice identifies macrophage heterogeneity in obstructive cholestasis.
Single-cell sequencing of a novel model of neonatal bile duct ligation in mice identifies macrophage heterogeneity in obstructive cholestasis.
复制标题
小鼠新生儿胆管连接的新型模型的单细胞测序鉴定了阻塞性胆汁淤积中的巨噬细胞异质性。
DOI:
10.1038/s41598-023-41207-0
复制
发表时间:
2023-08-29
影响因子:
4.6
通讯作者:
中科院分区:
文献类型:
--
作者:
Macrophages (MΦ) play a role in neonatal etiologies of obstructive cholestasis, however, the role for precise MΦ subsets remains poorly defined. We developed a neonatal murine model of bile duct ligation (BDL) to characterize etiology-specific differences in neonatal cholestatic MΦ polarization. Neonatal BDL surgery was performed on female BALB/c mice at 10 days of life (DOL) with sham laparotomy as controls. Comparison was made to the Rhesus Rotavirus (RRV)-induced murine model of biliary atresia (BA). Evaluation of changes at day 7 after surgery (BDL and sham groups) and murine BA (DOL14) included laboratory data, histology (H&E, anti-CD45 and anti-CK19 staining), flow cytometry of MΦ subsets by MHCII and Ly6c expression, and single cell RNA-sequencing (scRNA-seq) analysis. Neonatal BDL achieved a 90% survival rate; mice had elevated bile acids, bilirubin, and alanine aminotransferase (ALT) versus controls (p < 0.05 for all). Histology demonstrated hepatocellular injury, CD45+ portal infiltrate, and CK19+ bile duct proliferation in neonatal BDL. Comparison to murine BA showed increased ALT in neonatal BDL despite no difference in histology Ishak score. Neonatal BDL had significantly lower MHCII-Ly6c+ MΦ versus murine BA, however, scRNA-seq identified greater etiology-specific MΦ heterogeneity with increased endocytosis in neonatal BDL MΦ versus cellular killing in murine BA MΦ. We generated an innovative murine model of neonatal obstructive cholestasis with low mortality. This model enabled comparison to murine BA to define etiology-specific cholestatic MΦ function. Further comparisons to human data may enable development of immune modulatory therapies to improve patient outcomes.
登录
查看更多内容
影响因子:
3.7
作者:
Best J;Verhulst S;Syn WK;Lagaisse K;van Hul N;Heindryckx F;Sowa JP;Peeters L;Van Vlierberghe H;Leclercq IA;Canbay A;Dollé L;van Grunsven LA
通讯作者:
van Grunsven LA
影响因子:
4.3
作者:
Eden E;Lipson D;Yogev S;Yakhini Z
通讯作者:
Yakhini Z
影响因子:
5.1
作者:
通讯作者:
--
影响因子:
2.4
作者:
Davenport, M;Gonde, C;Howard, ER
通讯作者:
Howard, ER
影响因子:
4.8
作者:
Date, Dipali;Das, Riku;Mahabeleshwar, Ganapati H.
通讯作者:
Mahabeleshwar, Ganapati H.